RxDoctor Payments DataLook up a doctor →

Frank McGrew, MD

Cardiovascular Disease · Memphis, TNNPI 1922190396

Payments from drug & device makers

$2,128,701in general payments, 2019–2025

Across 1,902 payments — averaging $1119.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$424K
  • Novo Nordisk AS$385K
  • Novartis$373K
  • CSL Behring$372K
  • Medtronic$94K
  • Cvrx, Inc.$89K
  • plus $392K from 54 others

What the payments were for

  • Consulting fees$20,93518%
  • Speaking & faculty fees$63,35953%
  • Travel & lodging$5,8085%
  • Food & beverage$28,39824%
  • Education$6751%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen165$423,865
Novo Nordisk AS258$385,269
Novartis236$372,523
CSL Behring115$371,851
Medtronic(2 entities)101$93,538
Cvrx, Inc.26$89,195
Bayer142$66,637
Impulse Dynamics (USA) Inc.46$62,498
E.r. Squibb & Sons, L.L.C.60$38,989
Lexicon Pharmaceuticals, Inc.15$33,017
United Therapeutics Corporation12$31,225
Alnylam Pharmaceuticals Inc.31$20,491
Astrazeneca UK Limited1$20,425
Boehringer Ingelheim Pharma GmbH & Co.kg3$16,367
Boehringer Ingelheim International GmbH57$14,989
AstraZeneca88$12,341
American Regent2$11,223
Vifor (international) Ltd.5$9,750
Array Biopharma Inc3$9,225
Boehringer Ingelheim84$8,759
Lilly USA, LLC11$8,054
Johnson & Johnson58$7,935
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)20$4,463
Amarin Pharma, Inc.22$3,722
Pfizer48$3,325
Abbott45$1,287
Altathera Pharmaceuticals LLC3$1,124
Merck53$1,025
Novo Nordisk30$883
Actelion Pharmaceuticals US, Inc.42$787
Bristol Myers Squibb1$600
Sanofi-aventis U.S. LLC19$333
Boston Scientific5$326
ZOLL Circulation Inc2$287
Biotronik Inc.5$213
Esperion Therapeutics, Inc.11$184
Regeneron Healthcare Solutions, Inc.13$170
Lundbeck LLC8$157
Daxor Corporation3$154
Comsort, Inc1$150
ZOLL Respicardia, Inc.1$143
Atricure, Inc.1$135
Itamar Medical Inc2$130
Bridgebio Pharma, Inc.5$114
Arbor Pharmaceuticals, Inc.5$87
Kowa Pharmaceuticals America, Inc.5$79
Heartflow, Inc.4$75
Inspire Medical Systems, Inc.3$69
Vivaquant Inc, Dba Rhythm Express4$57
Scpharmaceuticals Inc.3$54
Philips North America LLC2$51
Astellas Pharma US Inc2$49
Daiichi Sankyo Inc.2$44
Portola Pharmaceuticals, LLC2$40
Vifor Pharma, Inc.2$37
Nuwellis, Inc.1$29
Kiniksa Pharmaceuticals, Ltd.1$27
Xeris Pharmaceuticals, Inc.1$24
Ironwood Pharmaceuticals, Inc1$22
Akcea Therapeutics, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,128,701 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$586,332
Medicare patients
907
Services billed
21,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis41$1,329,346
WainuaEplontersen Sodium15$599,194
EliquisApixaban586$537,949
EntrestoSacubitril/Valsartan417$401,160
Repatha SureclickEvolocumab382$338,140
Orenitram ErTreprostinil Diolamine11$316,566
OzempicSemaglutide216$228,999
XareltoRivaroxaban185$201,326
LetairisAmbrisentan11$143,508
JardianceEmpagliflozin148$140,500
FarxigaDapagliflozin Propanediol156$119,992
VascepaIcosapent Ethyl158$91,152
MultaqDronedarone Hcl46$71,658
KerendiaFinerenone66$53,412
NexletolBempedoic Acid113$51,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$3,325$1,867,295627 claims
AstraZenecaWainua, Farxiga, Brilinta$12,341$733,940192 claims
NovartisEntresto$372,523$401,160417 claims
Novo NordiskOzempic, Wegovy$883$258,362236 claims
Johnson & JohnsonXarelto$7,935$201,326185 claims
Boehringer IngelheimJardiance, Pradaxa$8,759$146,296173 claims
Sanofi-aventis U.S. LLCMultaq$333$71,65846 claims
BayerKerendia$66,637$53,41266 claims
Esperion Therapeutics, Inc.Nexletol$184$51,961113 claims
Lilly USA, LLCMounjaro$8,054$50,15148 claims
MerckVerquvo$1,025$29,08942 claims
AmgenCorlanor$423,865$9,54412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →